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Objective: To estimate the cost-effectiveness of introducing hepatitis B vaccine into routine infant
immunization services in Mozambique, which took place in the year 2001.
Methods: A decision analytic model was used to estimate the impact of hepatitis B vaccination. This
model was developed for the WHO to estimate the global burden of disease from hepatitis B. Cost data
of vaccine delivery and medical treatment related to hepatitis B infection were collected for the analysis.
Findings: The introduction of hepatitis B vaccine has increased the annual budget for immunization
services by approximately 56%. It is predicted that more than 4000 future deaths are averted annually by
the intervention. In the base case scenario, the incremental costs per undiscounted deaths averted
amount to US$436, and the costs per undiscounted DALY averted amount to US$36. Since the major
impact of hepatitis B vaccination will not start to be evident for at least another 40 years (deaths from
hepatitis B mainly occur between 40–60 years of age), the cost per DALY averted rises to US$47, when
using a discount rate of 3% on health effects. We found that the monovalent hepatitis B vaccine was
considerably more cost-effective than the hepatitis B vaccine in combination with DTP.
Interpretation: If policy makers value future health benefits equal to current benefits, the cost-
effectiveness of infant hepatitis B vaccination is in the range of other primary health care interventions
for which similar analysis has been undertaken.
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Introduction
Hepatitis B vaccine introduction in Mozambique
The Global Alliance for Vaccines and Immunization (GAVI),
launched in 1999, is an alliance between the private and public
sector committed to saving children’s lives and improving
health through the widespread use of vaccines. GAVI
collaborates closely with the Vaccine Fund, which provides
financing for immunization services and for purchasing new
and under-utilized vaccines against diseases such as hepatitis
B, yellow fever and haemophilus influenzae type b (Hib). By
March 2004, GAVI and the Vaccine Fund have helped finance
the introduction of hepatitis B vaccine into routine childhood
immunization services in 53 developing countries, of which
23 are in sub-Saharan Africa (http://www.vaccinealliance.
org).
Mozambique was among the first 13 countries to receive
awards for new vaccines granted by the Vaccine Fund. In a
proposal to GAVI and the Vaccine Fund, the Vice Minister of
Health in Mozambique requested support for introduction of
hepatitis B vaccine in combination with diphtheria, tetanus
and pertussis (DTP) vaccine. This proposal was endorsed by
all members of the Inter-Agency Coordinating Committee for
immunization services in Mozambique (Government of
Mozambique 2000). The proposal was approved by GAVI in
September 2000 and the first shipment of vaccines was
received in Mozambique in April 2001. The vaccine, a DNA
recombinant vaccine derived from hepatitis B surface antigen
(HBsAg), is procured through UNICEF’s supply division
(http://www.supply.unicef.dk).
The financial support received from the Vaccine Fund for
hepatitis B vaccine is currently planned to cease after 5 years.
Hence, by 2005 the Government of Mozambique must have
identified other funds to use for purchasing the vaccine, if the
decision is made to keep the vaccine in the schedule. To
prepare for this transition it is requested by GAVI that all
countries receiving support submit a ‘Financial Sustainability
Plan’ at the mid-point in funding (Financing Task Force of the
Global Alliance for Vaccines and Immunization, 2003).
Hence, the Ministry of Health in Mozambique submitted a
Financial Sustainability Plan in 2002 (Ministry of Health
2002). According to the plan, the main strategy to be adopted
to ensure continued funding for hepatitis B vaccine is
increased advocacy for resources from the State budget as
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well as from bilateral and multinational partners. A cost-
effectiveness analysis of the hepatitis B vaccine is likely to be
a useful tool for this strategy.
Evidence on cost-effectiveness and cost-benefit of hepatitis
B vaccine worldwide
The global literature is relatively rich in economic evaluations
of immunization against hepatitis B, especially studies from
industrialized countries. Several reviews have been written
that summarise the published economic literature to date
(Jefferson and Demicheli 1994; Beutels et al. 2002; Aggarwal
2002; Sadykova 2002). Beutel’s review covering economic
evaluations after 1994 reports five studies from very low
endemic countries, eight studies from low endemic countries,
four studies from intermediate endemic countries, and two
studies from highly endemic countries (Beutels 2001). These
studies build on the 90 economic evaluation studies reviewed
by Jefferson and Demicheli until 1994, of which 12 were from
developing countries (Jefferson and Demicheli 1994). The
overwhelming conclusion of these reviews is that the
introduction of the hepatitis B vaccine can be fully justified
on economic grounds, ‘economic’ grounds meaning either that
the cost-benefit ratio is positive or that the cost-effectiveness
ratio suggests the vaccine to be a good ‘buy’ for the public
health services, or both. A consensus statement in 2001
concluded that universal hepatitis B vaccination (of infants or
adolescents) is the most optimal strategy worldwide, except
for a few areas of lowest endemicity. In general, the higher the
endemicity, the more cost-effective it becomes to vaccinate in
the earlier years of life (Beutels 2001).
Study aims
The objective of the study was to estimate the costs per death
and Disability Adjusted Life Years (DALYs) averted from
introducing hepatitis B vaccine into routine, infant immuni-
zation services in Mozambique. The analysis was undertaken
from the point of view of society. We disregarded costs due to
adverse events of the vaccine, as these events are reported to
be minor (WHO 2000).
The type of analysis conducted was an incremental cost-
effectiveness analysis, being the most relevant when
deciding whether to keep hepatitis B vaccine within the
national immunization schedule. This is because the
immunization system already exists, and the intervention
only involves adding the hepatitis B vaccine to the schedule.
In practice, this means estimating the incremental costs
associated with introducing the hepatitis B vaccine, while at
the same time excluding all those costs that would have
been incurred anyway (Gold et al. 1996; Drummond et al.
1997).
Methods
Effectiveness estimation
Hepatitis B virus (HBV) infection leads to one of three
outcomes in an infected person: death from fulminant hepatitis
within days or weeks of clinical onset of disease, recovery
following asymptomatic or symptomatic acute HBV infection,
or the development of a chronic carrier state which may or
may not progress to clinical chronic liver disease, mainly
cirrhosis or hepatocellular carcinoma (HCC), also called
primary liver cancer (Kane et al. 1993).
A static model developed for WHO to estimate the global
burden of disease from HBV was used to estimate deaths
averted by introducing the vaccine in Mozambique (Gay
et al. 2001). The model includes age- and sex-specific
mortality that hepatitis B surface antigen (HBsAg) carriers
Table 1. Variables and values used in the epidemiological model when estimating deaths averted from hepatitis B vaccine in Mozambique
Variable Base case values Range used in
uncertainty analysis
Distribution used in
uncertainty analysis
Data source(s)
2001 birth cohort 794 650 – – Lopez et al. (2002)
Carrier rate 14% nationwide 12, 16% Normal 7 published studies and
expert opinion
Annual relative risk of
carriers dying of HBV
vs. other causes
1.05% 0.88%, 1.22% Triangular Data from Gambia, Taiwan,
Alaska (Beasley 1981; McMahan
1990; Whittle et al. 2002)
Rate of loss of surface
antigen after 25 years
1% 0.3%, 2.5% Triangular Literature review Gay et al. (2001)
Acute deaths as % of total
deaths from HBV
10% 8%, 11% Triangular Goldstein et al. (2003)
Coverage rate of the third
dose of DTP–hepatitis
B vaccine
80% 70, 85% Triangular Base case is official country
estimates (WHO 2002b).
Range is based on
PriceWaterhouseCoopers (2002).
Vaccine efficacy (3 doses) 95% 90, 99% Triangular WHO hepatitis B management
guidelines (WHO 2001b) for
base case and upper range. Lower
range based on assumption
about vaccine storage quality.
Vaccine wastage 25% None – MOH in Mozambique
Discount rate 0% and 3% – Alternative scenarios Gold et al. (1996)
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experience due to HBV associated hepatocellular carcinoma
(HCC) and cirrhosis. Deaths from other chronic sequelae of
HBV infection, such as chronic active hepatitis, are assumed
to be relatively small and ignored in the model (Gay et al.
2001).
Generally, the model operates by assuming that at any given
age, the number of chronic hepatitis B related deaths is
modelled by the following relationship:
DeathsAge j;Sex i ¼ SurvivorsAge j;Sex i £ P HBsAG
Carriage
at Age j; Sex i
£ R Risk of Death from
Hepatocellular carcinoma
or Cirrhosis for Age j; Sex i
The main advantage of this model is the limited data inputs
needed to estimate deaths. The model could be improved if
the incidence of acute infection could be predicted, as well
as the proportion of acute infections that transition to
chronic infections. However, little if any data are available
from developing countries on the incidence of acute
infections.
Risk of death from hepatocellular carcinoma (HCC) and
cirrhosis in HBsAg carriers
The value for the risk of death in HBsAg carriers was the
same as used in the WHO estimation of the burden of
hepatitis for the year 2000 (Gay et al. 2001; WHO 2002a). As
explained by Gay et al. (2001) this estimate is based on
incidence data of HCC and cirrhosis recorded between 1988
and 1997 by the National Cancer Registry of The Gambia as
well as prospective studies from Taiwan and Alaska (Beasley
et al. 1981; McMahon et al. 1990). The age- and sex-specific
mortality rates for HCC and cirrhosis were assumed to equal
the incidence of these conditions, as the life expectancy of
most cases is short. In the base case, where the average of the
rates derived for Taiwan and The Gambia is used, 27% of
male carriers and 9% of female carriers would be expected to
die from hepatitis before the age of 75 years, in the absence
of death from other causes. In the uncertainty analysis we
attach a distribution to this variable with a likely range (see
Table 1).
Prevalence of carriage
A key input parameter of the model is the prevalence of
carriage at 25 years. Above this age the prevalence is
estimated by the following relationship:
PAge i; Sex
Prevalence of carriage
at Age i; for given Sex
¼ PAge 25
Prevalence of carriage
at Age 25; both sexes
combined
£ exp{2aði2 25Þ}
Probability of remaining
HBsAg Positive
£ exp{2bSexi nþ1=ðn þ 1Þ}
Probability of not dying
from Hepatitis B related
liver disease
The following parameter values were used, derived from a
literature review (Gay et al. 2001): a ¼ 1%, bM ¼ 0.0133/
100 000, bF ¼ 0.0038/100 000, n ¼ 2.71.
A range is attached to a in the sensitivity analysis.
Unfortunately, there are no published studies available from
Mozambique on HBsAg carriage, not for individuals around
25 years old or for any other age groups. However, by
interviewing hepatitis B experts in Mozambique, the follow-
ing information was gathered:
† The main transmission route is believed to be horizontal
between young children under 5 years of age. The carrier
rate is believed to be around 20% for 3–4 year old children.
However, a proportion of these children clear carriage and
for 25 year olds the carriage is believed to be around 15%.
† Evidence is emerging that carriage rates decrease as people
move from rural to urban areas. Although this effect is not
entirely understood, it is hypothesized that this may be due
in part to changes in living conditions and reductions in
family sizes, as well as later age of mothers at the birth of
their first child, thereby reducing vertical transmission.
Based on this information and on a review of published
evidence from other sub-Saharan African countries, including
Madagascar, Nigeria, Zaire and Zimbabwe (Kew et al. 1977;
Jager et al. 1990; Kiire et al. 1990; Harry et al. 1994; Jacobs
et al. 1994; Boisier et al. 1996; Madzime et al. 1999), the best
estimates of carriage rates of 25 year olds in Mozambique are
the following:
† 15% carrier rate in rural areas, where 80% of the
Mozambican population lives;
† 10% carrier rate in urban areas, where 20% of the
Mozambican population lives.
In the base case we use an adjusted rate of 14% for 25 year olds.
Deaths from acute hepatitis B
The model does not estimate deaths from acute hepatitis
B. Instead, we assume that acute deaths amount to 10% of the
deaths from chronic hepatitis. This assumption is based on
findings from Goldstein et al. (2003) when estimating the
global reduction in hepatitis B burden from vaccination. As
with deaths from chronic hepatitis B, the risk of death from
acute disease is dependent on the age of infection. When using
the age structure of infection from sub-Saharan Africa,
Goldstein et al. (2003) finds that deaths from acute disease
amount to approximately 10% of all deaths from hepatitis
B. This assumption is varied in the uncertainty analysis.
Population data
Data on 2001 births in Mozambique were derived from the
United Nations Population Division (United Nations 2001).
When estimating the future population numbers for the 2001
birth cohort, we used country- and sex-specific life tables from
the WHO (Lopez et al. 2002). This ensures that co-morbidity
is taken into account in the model.
Ulla K Griffiths et al.52
DALY estimation
DALYs were estimated according to the formula published
in the 1996 Global Burden of Disease series (Murray and
Lopez 1996b). As suggested by Murray and Lopez, DALYs
were calculated both with and without discounting the value
of future life years with a 3% discount rate. Separate DALY
estimates were calculated for acute disease, cirrhosis and
HCC. The disability weight for an episode of acute hepatitis
varies according to age and is reported between 0.170 and
0.212 on a scale from 0 to 1 (0 being the least ‘damaging’
and 1 being the most ‘damaging’). The disability weight is
quoted as 0.33 for cirrhosis and 0.239 for HCC (Murray and
Lopez 1996b). The duration of disability for acute disease
was assumed to be 0.17 years (Murray and Lopez 1996a).
For cirrhosis and HCC the duration of disease varies
according to age and sex. For cirrhosis the duration is
between 5–10 years, and for HCC it is 0.7–2 years (Murray
and Lopez 1996a).
Programme cost estimation
It was decided to do a full cost analysis of the immunization
services, instead of only an incremental cost analysis
of hepatitis B vaccine delivery. This enabled us to estimate
the percentage change in costs due to the new vaccine.
The ingredient approach for costing was used. We
identified all resource items used for vaccine delivery
along with their respective quantities and unit costs (Kou
2002).
Data were to a large extent collected from the Expanded
Programme on Immunization (EPI) central offices. Approxi-
mations and assumptions were required to estimate the
allocation of staff time and vehicles to immunization
services, as these resources are shared with other health
services. Capital items were annualized using a 3% discount
rate.
We estimated the incremental costs of introducing the DTP-
hepatitis B combination vaccine as well as hepatitis B vaccine
in monovalent form. Hepatitis B vaccine in combination with
other antigens already in the schedule does not involve any
additional injections and is therefore considerably simpler to
introduce than a vaccine in a separate vial (Kou 2002).
Furthermore, since the combination vaccine was introduced in
the same vial size as before (10 dose vial), it does not take up
more space in the cold chain either. However, these
advantages might be outweighed by the relatively large
price difference between the two types of vaccines. Presently,
the price of DTP-HepB combination vaccine is around US$1.2
per dose (DTP vaccine alone is only around US$0.12), but
monovalent hepatitis B vaccine can be procured from
UNICEF for only around US$0.27 per dose (UNICEF
2004). Delivery costs of the monovalent vaccine include
syringes, safety boxes, waste management of used syringes,
transport and storage in addition to the vaccine. We assessed
the impact on the cold chain of introducing a monovalent
vaccine by using the WHO ‘vaccine volume calculator’
(WHO 2001a).
Future costs saved
Future health service costs saved from the avoidance of
treating complications of hepatitis B include the acute
morbidity associated with the initial infection as well
as chronic liver disease due to HBV, such as chronic
active hepatitis, chronic persistent hepatitis, cirrhosis and
hepatocellular carcinoma. All these conditions involve out-
patient visits where either treatment takes place or patients are
referred to a higher level of care, which in some cases will lead
to inpatient admission.
We estimated the annual number of acute and chronic
morbidity cases by using a model similar to the one used for
the effectiveness estimates (Gay et al. 2001). The model
estimates were compared to available surveillance and
hospital inpatient data from Maputo for verification. Since
the numbers were in similar ranges, we concluded that our
model estimates were robust. Data on resource utilization and
unit costs of treatment were collected from the government
health sector as well as from traditional healers. We did
not collect data from the formal, private health sector as
these facilities still cover only a very small proportion of
the Mozambican population. Instead, we assumed that the
traditional healer costs covered all out-of-pocket costs of the
patients.
The assumptions made when estimating treatment costs are
summarised in Table 2. Cost data for inpatient care were
collected at Maputo Central Hospital, which is a regional and
national referral hospital with 1500 beds. The population
served by the hospital from Maputo is about 1.1 million. There
are no figures on the number of referrals from other districts.
Costs of treatment consist of hospital overhead costs as well as
patient-specific costs related to drugs and laboratory tests. Due
to resource constraints, it is not possible for the hospital to
provide optimal treatment to patients with acute or chronic
hepatitis and the drugs used are considerably less expensive
than those that comply with international treatment standards
(Core Working Party 2000). For patients with cirrhosis and
hepatocellular carcinoma, there is essentially no treatment
available in Mozambique.
Generalized unit costs for outpatient care in African settings
were used to approximate government outpatient costs in
Mozambique (Goodman et al. 2000). Treatment costs from
traditional healers were collected from the Traditional
Medicines Unit at the National Institute of Health in
Mozambique. The costs of receiving treatment from a
traditional healer essentially consist of the consultation fee
as well as the cost of a traditional herbal tea, which is usually
prescribed for HBV-related symptoms.
After estimating the approximate annual treatment costs due
to HBV, we estimated the proportion of treatment costs that
will be saved in the future due to vaccination by multiplying
these costs by the vaccination coverage rate and the vaccine
efficacy. Finally, we discounted future cost savings to their
present value using a 3% discount rate and assuming that the
costs will be incurred on average 40 years into the future.
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Table 2. Variables and input values used to calculate treatment costs saved from preventing HBV-related disease in Mozambique (2001 US$a)
Variable Base case Range used in
uncertainty analysis
Distribution used in
uncertainty analysis
Data source
Annual no. of morbidity
cases due to hepatitis
B virus (HBV):
Acute HBV infections No. of patients 22 869 Point estimate Model estimate
Chronic morbidity No. of patients 2 058 Point estimate Model estimate
Government health service costs:
Hospital inpatient No. of admissions in
whole country
12 000 Standard deviation of 2000 Normal Maputo Quarternary Hospital, assumption
about limited access to care
Average length of stay
(days)
8 5, 11 Triangular Maputo Quarternary Hospital
Cost per day, including
drugs
US$5 3, 7 Triangular Maputo Quarternary Hospital
Hospital outpatient facility % of outpatient visits at
hospital
0.32 Point estimate Goodman et al. (2000)
No. of visits 3 840 Standard deviation of 500 Normal Assumption that 50% of patients use
government facilities
Cost per visit US$3 2, 4 Triangular Goodman et al. (2000)
Health centre outpatient No. of visits 8 160 Standard deviation of 1000 Normal Assumption that 50% of patients use
government facilities
Cost per visit US$1 Point estimate
Laboratory tests % patients who have laboratory
test
5% Point estimate Maputo Quarternary Hospital
Cost per laboratory test US$4 Point estimate Maputo Quarternary Hospital
Out-of-pocket/private costs to traditional healers:
Visits to traditional healer % patients seeking care 80% 70%, 90% Triangular Assumption
Visits to traditional healer No. of visits per
patient
3 2, 5 Triangular Assumption
Cost of treatment Costs per consultation Maputo: US$3 Maputo: US$2, 4 Triangular Traditional Medicines Unit,
Other urban: US$0.63 Other urban: US$0.56, 0.69 National Institute of Health,
Mozambique
Rural: US$0.21 Rural: US$0.15, 0.27
Cost of traditional tea
per person
US$0.40 Point estimate Traditional Medicines Unit, National
Institute of Health, Mozambique
*The exchange rate used when calculating the values was 24 000 MTS for US$1.
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Cost-effectiveness
Cost-effectiveness ratios were calculated by subtracting the
predicted, discounted, annual treatment costs savings from the
annual vaccine delivery costs and dividing this number by the
predicted number of hepatitis B deaths and DALYs averted
from vaccination. Cost-effectiveness ratios were calculated
with and without discounting future health effects by 3%
per year. Future costs were always discounted by 3% per
annum.
Uncertainty analysis
Based on assumed ranges and distributions of the uncertain
variables used in the model, a probabilistic uncertainty
analysis was done by a Monte Carlo simulation (2000
simulations) using Crystal Ballq, giving prediction intervals
around the mean cost-effectiveness ratios (Decisioneering Inc.
2003). The input values used in the model for the base case, as
well as the ranges and distributions used for the uncertainty
analyses, are summarised in Tables 1 and 2.
Figure 1. Predicted deaths from chronic hepatitis for 2001 birth cohort in a scenario with no vaccination
Table 3. Total annual immunization services costs in Mozambique and incremental costs of hepatitis B vaccine introduction (2001 US$)a
Cost category Without hepatitis
B vaccine
% of total Incremental costs
of DTP–hepB vaccinec
Incremental costs of
hepatitis B monovalentd
Capital costs
Vehicles 221 230 5.8 0 0
Storage 223 188 5.8 0 0
Social mobilization 0.0 7 580 7 580
Training 0.0 49 605 49 605
Total capital costs 444 418 11.6 57 185 57 185
Recurrent costs
Personnel 1 090 340 28.5 0 0
Vaccines 868 047 22.7 2 106 843 616 761
Auto disposable syringes 171 500 4.5 0 212 357
Disposable syringes 21 150 0.6 0 0
Safety boxes 35 420 0.9 0 11 869
Surveillance 226 266 5.9 0 0
Transport operating & maintenance 485 970 12.7 0 24 299
Cold chain storage 487 513 12.7 0 24 376
Total recurrent costs 3 386 207 88.4 2 106 843 889 661
TOTAL COSTS 3 830 625 100.0 2 164 028 946 846
Percentage increase 56% 25%
Costs per fully immunized childb 6.60 10.34 8.24
a The exchange rate used when calculating the values was 24 000 MTS for US$1.
b Assuming a target population of 725 000 and vaccine coverage rate of 80%.
c Assumed price of DTP–hepB vaccine: US$1.078 per dose.
d Assumed price of hepatitis B vaccine: US$0.2862 per dose.
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Results
Effectiveness
Figure 1 illustrates the deaths from chronic hepatitis B
predicted by the model with base case parameters in a
situation with no hepatitis B vaccine introduced for the 2001
birth cohort. A total of 5767 deaths from acute and chronic
disease are predicted in the base case scenario, with the
majority occurring in the age group 35–56 years. With a birth
cohort of 794 650 children, it is thus predicted that 0.73% of
the cohort will die from HBV-related disease in the absence of
vaccination.
In the base case scenario it is predicted that 4383 deaths and
53 275 DALYs are averted by the introduction of hepatitis B
vaccine, and once these are discounted, taking into account
that the deaths are averted on average 40 years into the future,
this reduces to the equivalent of 1043 deaths and 40 752
DALYs annually.
Programme costs
Table 3 presents the annual costs of immunization services
and the incremental costs of introducing hepatitis B vaccine,
in combination with DTP or as monovalent vaccine. In 2001,
total immunization services costs would have been approxi-
mately US$3.83 million without hepatitis B vaccine introduc-
tion, or around US$6.6 per fully immunized child. When
assuming that hepatitis B vaccine was delivered for the full
financial year, the costs increased to US$5.99 million or
US$10.3 per fully immunized child. This is a 56% increase in
total costs. It can be seen that the large majority of incremental
costs, US$2.1 million, were due to the costs of vaccines. While
Mozambique used to pay US$0.079 per dose of DTP vaccine,
the price per dose of the vaccine combined with hepatitis B is
US$1.08. Other additional costs incurred were social mobil-
ization and training of staff, together making up 2.6% of the
incremental costs.
Introduction of the monovalent vaccine would only result in a
25% increase in total costs. With the vaccine volume
calculator we estimated that introduction of the monovalent
vaccine would increase the vaccine storage volume by 29%.
According to the Ministry of Health logistician, this increase
can be accommodated at national and provincial level with the
present cold chain capacity. However, at district and health
facility level the cold chain capacity might present some
limitations, even though these could perhaps be accommo-
dated with better space management. We assumed a 5%
increase in cold chain and transport costs to cover for the
additional work load in logistics.
Future costs saved
We estimate that total treatment costs from HBV-related
illnesses amounted to US$540 509 in 2001. Out-of-pocket
costs amount to 7% of the total. When discounted by 3% per
year for 40 years, annual treatment costs reduce to
US$165 697. Total potential discounted savings are
US$125 930 per year. When using the assumptions summa-
rised in Table 2, the probabilistic uncertainty analysis shows
that the treatment costs saved lives in a 95% prediction
interval of US$73 880–200 607. Hence, a fairly wide predic-
tion interval due to the uncertainty about these costs.
Cost-effectiveness
Table 4 presents the cost-effectiveness ratios in the base case
scenario. At zero discount rate, the incremental cost for
combination vaccine is US$436 per death averted and US$36
per DALY averted. When discounting future health effects at
3% per year, the incremental cost-effectiveness ratio
increases to US$1833 per death averted and US$47 per
DALY averted. The cost-effectiveness results for the mono-
valent vaccine are considerably more favourable. At zero
discount rate, the incremental cost for the monovalent vaccine
is US$178 per death averted and US$15 per DALY averted.
When discounting future health effects at 3% per year, the
Table 4. Incremental cost-effectiveness of hepatitis B vaccine in Mozambique: base case scenario (2001 US$)
Intervention Net costs Total
deaths
Total
DALYs
Incremental
costs
Incremental
deaths
Incremental
DALYs
Cost-effectiveness
ratio (deaths)
Cost-effectiveness
ratio (DALYs)
Combination vaccine
Undiscounted results
No hepatitis B vaccination 165 697 5 767 70 099
Hepatitis B vaccination 2 077 866 1 384 16 824 1 912 169 4 383 53 275 436 36
Discounted results (3%)
No hepatitis B vaccination 165 697 1 373 53 621
Hepatitis B vaccination 2 077 866 329 12 869 1 912 169 1 043 40 752 1 833 47
Monovalent vaccine
Undiscounted results
No hepatitis B vaccination 165 697 5 767 70 099
Hepatitis B vaccination 946 846 1 384 16 824 781 149 4 383 53 275 178 15
Discounted results (3%)
No hepatitis B vaccination 165 697 1 373 53 621
Hepatitis B vaccination 946 846 329 12 869 781 149 1 043 40 752 749 19
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incremental cost-effectiveness ratio increases to US$749 per
death and US$19 per DALY averted.
Uncertainty analysis
The probabilistic uncertainty analysis reveals that the cost-
effectiveness ratios are located in wide prediction intervals.
The 95% prediction intervals are summarised in Table 5. The
uncertainty chart is illustrated in Figure 2 for costs per
discounted DALY averted. The uncertainty chart shows to
what extent the cost-effectiveness ratio is sensitive to
uncertain variables, as defined in Tables 1 and 2. The overall
uncertainty is a combination of the ratio’s uncertainty to the
uncertain variables as defined in the model, and the
uncertainty of the variables. It can be seen that the cost-
effectiveness result is most sensitive to HBsAg prevalence at
25 years of age and to the rate of clearance of HBsAg. These
are thus the most important assumptions in the model. This is
not surprising, as these are the variables that determine the
predicted number of deaths from hepatitis B. In order to
narrow the prediction interval, more accurate information on
these two variables needs to be generated.
Discussion
This study has found that more than 4000 premature deaths
will be averted in Mozambique through routine hepatitis B
vaccination of infants in the 2001 birth cohort. However, most
of these benefits will not take place for around 40–50 years,
when the major long-term complications would otherwise take
place. The cost-effectiveness of introducing the hepatitis B
vaccine into routine vaccination services costs US$15 per
discounted DALY for monovalent vaccine and US$36 per
discounted DALY for combination vaccine. When health
effects are discounted, the cost per DALY averted increases to
US$19 and US$47 for monovalent and combination vaccine,
respectively.
The relatively large difference between the discounted and
non-discounted estimates illustrates that, in the case of
hepatitis B vaccine, it is crucial to report both approximations.
When both results are reported, it can be left to policy makers
to determine to what extent they value a future life as much as
a present, thereby deciding which result to use when comparing
the cost-effectiveness ratios of different health interventions.
Comparison with cost-effectiveness evidence of hepatitis B
vaccine from other countries has several problems: different
cost base years, different methodologies and different units of
effect. For example, in the only published economic
evaluation to date based on real experience of introduction
of hepatitis B vaccine in a highly endemic country, Hall et al.
(1993) estimate the cost of averting a death from liver cancer
in The Gambia to be in the range US$150–200, but this is at
1993 prices, and the study does not discount the future health
effects. Other studies have modelled hypothetical cost-
effectiveness ratios in developing country settings, ranging
from US$16 per life year gained in India (Aggarwal et al.
2003), to US$21 per Quality-Adjusted Life Year gained in a
group of developing countries (Shepard et al. 1995), to US$58
per life year saved in Israel (Sadykova 2002). Therefore, while
comparison is difficult due to different outcome measures and
different cost base years, it can be concluded that the cost-
effectiveness of the monovalent vaccine in Mozambique has
around the same, or more favourable, cost-effectiveness ratio
Figure 2. Costs per DALYs averted: sensitivity chart
Table 5. Uncertainty analysis of cost-effectiveness of DTP–hepatitis B
combination vaccine
Outcome measure Mean value 95% interval
C/E (discounted deaths) 2034 (1404, 3067)
C/E (discounted DALYs) 52 (36, 78)
C/E (non-discounted deaths) 496 (329, 777)
C/E (non-discounted DALYs) 40 (27, 59)
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compared with other developing country settings. Clearly the
combination vaccine in Mozambique has a less favourable
cost-effectiveness ratio, due to the considerably higher unit
cost of the vaccine.
The most pressing question faced by health policy makers in
Mozambique is whether the hepatitis B vaccine should be
financed from public funds, based on the vaccine delivery
costs and the estimated cost-effectiveness of the vaccine.
However, there is very limited cost-effectiveness infor-
mation on other health interventions in Mozambique to
compare with the results in this study, in order to make
resource allocation decisions based on comprehensive and
up-to-date cost-effectiveness evidence. To our knowledge,
this is the first cost-effectiveness study of a health
intervention in Mozambique.
When comparing the cost per DALY averted with other cost-
effectiveness studies of health interventions in sub-Saharan
Africa, and in comparison with the annual gross national
income per capita in Mozambique of US$210, the intervention
can be considered moderately cost-effective. Goodman et al.
(2000) illustrated that preventive interventions against malaria
in a very low income country were in the range of US$4–85
per discounted DALY averted. Hence, the cost-effectiveness
of the monovalent hepatitis B vaccine is in the lower range of
interventions to prevent malaria, and the combination hepatitis
B vaccine in the middle range.
In the absence of AIDS-related deaths in Mozambique, the
cost-effectiveness of hepatitis B vaccine would in no doubt be
more favourable. Deaths from hepatitis B mainly occur
between the ages of 40–60 years. However, due to the
AIDS epidemic, many people have died before this age.
One of the weaknesses of our analysis is that herd immunity is
not taken into account when estimating the long-term effect of
the vaccine. This means that we are likely to overestimate the
cost-effectiveness ratio. Another weakness is that the data on
treatment costs are only based on data collection from one
health care institution. Moreover, we have not included
treatment costs of formal, private health institutions, such as
private hospitals, and we have not tried to estimate the
proportion of patients who seek higher quality health care
overseas. Another major weakness with regard to treatment
costs is that it is impossible to predict what type of
technologies for treatment will be available for hepatitis B
related illnesses in Mozambique in 40 years time. In our
analysis we have assumed that the costs of future treatment
will be similar to today, but this assumption is very uncertain.
If the Mozambican health sector were to invest in improved
and more expensive treatment of hepatitis B, the cost-
effectiveness of the vaccine would improve.
Given these economic arguments, and given the greatly
increased but short-term financial support available for
funding new and under-utilized vaccines, this study comes
at an important time. With some early experiences of the first
phase of GAVI already reported from the field, with data on
coverage, implementation success and vaccine costs, cost-
effectiveness ratios will reflect the reality more closely than
previous studies that cover generalized groups of countries
and contain major data assumptions. Therefore, the improved
accuracy and certainty of the cost-effectiveness results will
add to the debate on financing and vaccine sustainability.
Also, the cost-effectiveness model developed for this study
can be readily applied to other countries.
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